Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Top Cited Papers
- 5 March 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (10) , 1098-1110
Abstract
Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML). We report the long-term efficacy and safety of MRD-guided preemptive azacitidine treatment to prevent relapse in the phase 2 Relapse Prevention With Azacitidine (RELAZA2) trial. Patients with MDS or AML after either intensive chemotherapy only or consecutive allogeneic stem cell transplantation were prospectively screened for imminent relapse by molecular MRD assessment. Patients who became MRD positive (MRDpos) during screening received azacitidine for up to 2 years to prevent relapse. The primary end point was the proportion of patients alive and relapse-free 6 months after azacitidine start. Of 357 patients screened, 119 (33.3%) became MRDpos, of whom 95 (79.8%) were eligible for azacitidine treatment. The primary end point was met; 60 (63%) patients were relapse free (95% confidence interval, 54-71; P< .0001) 6 months after azacitidine initiation with no new safety signals. Of 60 patients achieving MRD response during the first 6 cycles of azacitidine, 31 (52%) maintained response without hematological relapse for ≥2 years after azacitidine initiation. The median treatment-free duration after azacitidine discontinuation was 20.8 months; the longest ongoing response was 104 months. After a median follow-up of 6.6 years, 15 initial responders (25%) remained alive and in remission. Among screened patients who remained continuously MRD negative, 60-month overall survival and relapse-free survival were 88% and 79%, respectively. Patients with continuously negative MRD display a very favorable prognosis. Most patients with MRD positivity can be effectively treated with azacitidine with potential long-term remission even after termination of azacitidine. This trial was registered at www.clinicaltrials.gov as #NCT01462578.Keywords
This publication has 29 references indexed in Scilit:
- Azacitidine combined with interferon‐α for pre‐emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II studyBritish Journal of Haematology, 2024
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trialThe Lancet Oncology, 2018
- Measurable residual disease testing in acute myeloid leukaemiaLeukemia, 2017
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trialLeukemia, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidineLeukemia, 2009
- Minimal residual disease levels assessed by NPM1 mutation–specific RQ-PCR provide important prognostic information in AMLBlood, 2009
- Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markersLeukemia, 2001